Pregabalin for neuropathic pain based on recent clinical trials

Brett R. Stacey, Jon N. Swift

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Pregabalin is a ligand for the α-2-δ subunit of voltage-gated calcium channels with anticonvulsant, analgesic, and anxiolytic properties. It has predictable absorption across the gastrointestinal tract, is neither metabolized nor protein-bound, and has minimal drug-drug interactions. It is effective with two or three-times daily dosing in a dose range of 150 to 600 mg daily. Seven published prospective, randomized clinical trials in postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPN) demonstrate pain relief, decreased sleep interference, and improvements in several secondary outcome measures. The 50% responder rates for PHN and DPN compare favorably with other first-line agents for neuropathic pain. Pregabalin is well tolerated in most patients with infrequent severe adverse effects. Pregabalin is an important addition to the treatment armamentarium for neuropathic pain.

Original languageEnglish (US)
Pages (from-to)179-184
Number of pages6
JournalCurrent pain and headache reports
Volume10
Issue number3
DOIs
StatePublished - Jun 1 2006

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Fingerprint Dive into the research topics of 'Pregabalin for neuropathic pain based on recent clinical trials'. Together they form a unique fingerprint.

  • Cite this